-
公开(公告)号：US20220105134A1
公开(公告)日：2022-04-07
申请号：US17490582
申请日：2021-09-30
发明人： Zhiyuan Cao , Lei Xiao , Yuzhe Peng , Wei Ding , Wensheng Wang
IPC分类号： A61K35/17 , C07K14/47 , C07K14/725
摘要： The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
-
公开(公告)号：US20240299452A1
公开(公告)日：2024-09-12
申请号：US18441683
申请日：2024-02-14
发明人： Chengfei Pu , Dongqi Chen , Xiaogang Shen , Le Tian
CPC分类号： A61K35/17 , A61K31/436 , A61K39/4612 , A61K39/4613 , A61K39/4631 , A61K39/464411 , A61K39/464441 , A61P35/00 , C07K14/57 , C07K16/2803 , A61K2239/13 , A61K2239/21 , A61K2239/58
摘要： Embodiments of the present disclosure relate to compositions and methods of enhancing anti-tumor activities of modified cells, the method comprising: administering an effective amount of the modified cells to a subject having a solid tumor; and administering an effective amount of an agent to the subject, the agent comprising rapamycin, wherein the modified cells inhibit growth of the solid tumor in the subject, and wherein the anti-tumor activities in the subject are greater than those in a subject that is administered with an effective amount of modified cells but without the agent.
-
公开(公告)号：US20240199760A1
公开(公告)日：2024-06-20
申请号：US18540269
申请日：2023-12-14
发明人： Xiaogang SHEN , Wensheng WANG , Xudong TANG , Chengfei PU , Zhao WU , Lei XIAO
IPC分类号： C07K16/32 , A61K47/68 , A61K51/10 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N5/0783
CPC分类号： C07K16/32 , A61K47/6851 , A61K51/1045 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2809 , C12N5/0636 , C07K2317/31 , C07K2317/569 , C07K2319/03 , C12N2502/30
摘要： The present disclosure describes compositions and methods for treating solid tumors expressing mesothelin (MSLN) using chimeric antigen receptor (CAR) T cell therapy. The compositions comprise CARs with an extracellular domain that specifically binds MSLN. The extracellular domain comprises a single variable domain (VHH) antibody that targets MSLN. Polynucleotides encoding the anti-MSLN CAR constructs are provided. Pharmaceutical compositions comprising CAR T cells expressing the anti-MSLN CARs are also described. The CAR T cells demonstrate cytotoxicity against MSLN-expressing tumor cells in vitro and anti-tumor activity in vivo. Methods are provided for generating the CAR T cells by transfecting T cells with lentiviral or retroviral vectors carrying anti-MSLN CAR encoding sequences. The anti-MSLN CAR T cell therapy described herein provides an effective approach for treating solid tumors expressing MSLN, such as mesothelioma, ovarian cancer, pancreatic cancer, and lung cancer.
-
公开(公告)号：US20240075061A1
公开(公告)日：2024-03-07
申请号：US18065301
申请日：2022-12-13
发明人： Wensheng Wang , Dongqi Chen , Chengfei Pu , Zhao Wu , Lei Xiao , Zhiyuan Cao , Le Tian
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C12Q1/6886
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4622 , A61K39/4631 , A61K39/464412 , A61K39/464454 , A61P35/00 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.
-
公开(公告)号：US11833174B2
公开(公告)日：2023-12-05
申请号：US17023835
申请日：2020-09-17
发明人： Zhiyuan Cao , Chengfei Pu , Dongqi Chen , Wei Ding
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , C07K16/30 , C07K16/40
CPC分类号： A61K35/17 , C07K14/7051 , C07K14/70578 , C07K16/3007 , C07K16/3053 , C07K16/40 , C07K2319/03
摘要： Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.
-
公开(公告)号：US20230032871A1
公开(公告)日：2023-02-02
申请号：US17812521
申请日：2022-07-14
发明人： Zhiyuan Cao , Wei Ding , Guiting Han , Lei Xiao , Le Tian
IPC分类号： A61K31/519 , A61K38/17 , A61K38/21 , A61K38/20 , A61K38/19
摘要： The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance proliferation of chimeric antigen receptor (CAR) T cells in a patient, The method comprises administering to the patient an effective amount of a pharmaceutical composition comprising lymphocyte activation agents and one or more recombinant viral particles comprising a polynucleotide encoding a CAR, wherein the proliferation of CAR T cells in the patient is greater as compared to a patient administered with the one or more recombinant viral particles but without the lymphocyte activation agents.
-
公开(公告)号：US20220265708A1
公开(公告)日：2022-08-25
申请号：US16961418
申请日：2019-01-10
发明人： Lei Xiao , Chengfei Pu , Zhiyuan Cao , Zhao Wu , Li Mao , Mao Bi
IPC分类号： A61K35/17 , C12N5/0783 , C12N15/62 , C12N15/86
摘要： The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.028 秒)
